• Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

    Source: Nasdaq GlobeNewswire / 31 Oct 2024 07:30:00   America/Chicago

    AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.

      
    Event details:
      
    Date:Thursday, November 7th
    Time:8:30 a.m. Eastern Time
    Audio Webcast:https://www.CassavaSciences.com/company-presentations
    Or
    Audio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy
      

    A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.

    About Cassava Sciences, Inc.
    Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

    Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

    For more information, please visit: https://www.CassavaSciences.com

    For More Information Contact:

    Investors
    Sandya van der Weid
    svonderweid@lifesciadvisors.com

    Media
    Sitrick And Company
    Mike_Sitrick@Sitrick.com

    Company
    Eric Schoen, Chief Financial Officer
    (512) 501-2450
    ESchoen@CassavaSciences.com


    Primary Logo

Share on,